Literature DB >> 18821100

Drug-induced hyperbilirubinemia and the clinical influencing factors.

Young-Mi Ah1, Young-Mi Kim, Min-Jung Kim, Young Hee Choi, Kyoung-Ho Park, In-Ja Son, Sang Geon Kim.   

Abstract

Hyperbilirubinemia may accompany harmful effects such as jaundice, brain dysfunction, and pharmacokinetic alterations of drugs. Clinical drugs are the important causes of hyperbilirubinemia, especially for patients with certain pathologic conditions or with genetic variations. This article reviews hyperbilirubinemic pathophysiology with respect to the effects of clinical drugs. In addition, this review introduces a new formula that may be utilized to estimate the annual occurrences of drug-induced hyperbilirubinemia in a hospital. Variations in the genes of UDP-glucuronosyltransferases, organic anion-transporting polypeptides and multidrug resistance proteins are the predisposing factors for drug-induced hyperbilirubinemia; therefore, their genetic and ethnic polymorphisms are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821100     DOI: 10.1080/03602530802341133

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  5 in total

1.  Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.

Authors:  Kimberly S Collins; Ingrid F Metzger; Brandon T Gufford; Jessica B Lu; Elizabeth B Medeiros; Victoria M Pratt; Todd C Skaar; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2019-12-30       Impact factor: 3.922

2.  Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies.

Authors:  Coralea Stephanou; Stella Tamana; Anna Minaidou; Panayiota Papasavva; Marina Kleanthous; Petros Kountouris
Journal:  J Clin Med       Date:  2019-11-09       Impact factor: 4.241

3.  Increased Total Serum Bilirubin Level Post-Ibuprofen Use Is Inversely Correlated with Neonates' Body Weight.

Authors:  Zon-Min Lee; Yao-Hsu Yang; Ling-Sai Chang; Chih-Cheng Chen; Hong-Ren Yu; Kuang-Che Kuo
Journal:  Children (Basel)       Date:  2022-08-07

4.  Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition.

Authors:  Jose L Ulloa; Simone Stahl; James Yates; Neil Woodhouse; J Gerry Kenna; Huw B Jones; John C Waterton; Paul D Hockings
Journal:  NMR Biomed       Date:  2013-04-07       Impact factor: 4.044

5.  Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis.

Authors:  Young Hee Choi; Chang Ho Lee; Myong Suk Ko; Hyun Joo Han; Sang Geon Kim
Journal:  Toxicol Res       Date:  2015-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.